A phase 2 trial of RAG-17 has begun for SOD1-related ALS
Related topics
Patients have begun receiving RAG-17 in a phase 2 clinical trial for amyotrophic lateral sclerosis (ALS) linked to mutations in the SOD1 gene. The trial follows earlier safety testing and will assess whether the treatment can slow disease progression in this genetic group.
Why this matters
This development concerns people with SOD1 mutations, not people with ALS generally. It does not yet show that RAG-17 slows ALS or change treatment; those questions require results from the trial.
Limitations and context
The information comes from a Curalysis research roundup summarising an ALS News Today report, not from the trial's primary publication. The source does not provide the trial's size, design, outcome data, or peer-review status. Earlier testing is described as showing safety, but no supporting results are given.